Alessandro Gozzetti, Rosaria Crupi, Marzia Defina and Monica Bocchia
we read with great interest the Case study by Ludwig and Zojer in which they describe a case of a 51-year-old man with igG λ stage iii B multiple myeloma who presented with renal impairment associated with urinary secretion of free λ chains (renal recovery with lenalidomide in a patient with bortezomib-resistant multiple myeloma. nat. rev. Clin. Oncol. 7, 289-294; 2010 2 showed that patients with relapsed myeloma carrying a deletion of 17p13 were refractory to lenalidomide and had an inferior outcome compared with patients not carrying this abnormality. Patients with either a deletion of 13q or a t(4;14) translocation experienced a median time to progression and overall survival comparable with those without these cytogenetic abnormalities, whereas patients with a deletion of 17p13 had a significantly worse outcome, with a median time to progression of 2.22 months (hazard ratio 2.82; P <0.001) and median overall survival of 4.67 months (hazard ratio 3.23; P <0.001). the mechanisms of resistance to lenalidomide are unknown. indeed, the second of our two cases seems to confirm that.
in conclusion, these cases suggest that patients with myeloma who have a deletion of 17p are likely to be refractory to treatment with lenalidomide, whereas patients without this deletion seem to respond to lenalidomide. we believe this information needs to be confirmed in larger studies, but could be useful for more targeted treatment strategies. 
